Biocytogen’s APAC Business Development team is pleased to announce our participation in BIO KOREA 2025, taking place from May 7–9 in Seoul, South Korea. We will be exhibiting at Booth H21 and are available for one-on-one meetings throughout the event.
Come and visit our booth to learn more about how our RenMice® fully human antibody discovery platform can accelerate the development of innovative therapeutics. Additionally, our advanced gene-edited models and comprehensive preclinical pharmacology services are designed to support the effective evaluation and optimization of drug candidates. We look forward to connecting with partners and collaborators at BIO KOREA 2025.
Biocytogen’s RenBiologics and BioMice business divisions have been widely recognized by Korean and global companies. In March of 2024, we initiated a collaboration with ABL Bio aimed at developing new bispecific ADCs. As of December 31, 2024, we have successfully established approximately 200 therapeutic antibody agreements and over 50 target-nominated RenMice® licensing projects worldwide.
Additionally, multiple top 20 Korean companies utilize our BioMice models or services for their drug development. Globally, our models have been sold to 20+ countries and regions, and we have completed 5300+ drug evaluation projects for approximately 900 partners.
Interested in exploring partnership opportunities with us to benefit your drug discovery and development? Schedule a 1-on-1 meeting with us today!
